Roche cuts MS relapses up to 58.5% with fenebrutinib as FDA weighs an oral rival to its own Ocrevus
The FDA has accepted Roche’s fenebrutinib filing under Priority Review for both relapsing and primary progressive multiple sclerosis, potentially creating a high-efficacy oral alternative across disease forms currently treated very differently.
